A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
← catalyst calendarNCT07546760 · readout in 169 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
28estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-20 | actual | When the study began enrolling |
| Primary completion | 2027-02-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatic Impairment
Interventions
- Drug: AZD6234
- Drug: AZD9550
Primary outcomes
what the primary-completion date above is the date OFPK parameters AUCinf
measured Day 0 through Day 56
PK parameters AUClast
measured Day 0 through Day 56
PK parameters Cmax
measured Day 0 through Day 56
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed